EPHA4

Across TCGA pan-cancer cohorts, EPHA4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EPHA4 data layer compared with 27 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EPHA4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated EPHA4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where EPHA4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.806	0.254	.001	36	view →
HNSC	DFS	Quartile	All	0.722	0.440	.004	22	view →
LUAD	DFS	Tertile	II,III,IV	0.341	0.840	.015	12	view →
GBM	DFS	Median	All	0.263	0.469	.025	7	view →
UCEC	DFS	Tertile	II,III,IV	1.000	0.576	.016	4	view →
CCRCC	OS	Quartile	III,IV	0.985	0.714	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EPHA4–PDAC (OS)

Open the PDAC breakdown →